Search Results 1-10 of 14872 for TNF

  1. Examining clinical and genetic factors that impact response to anti-TNF agents in patients with IBD

    Approved in 1998 for use in treating Crohn's disease and subsequently in 2005 for treating ulcerative colitis, anti-tumor necrosis factor (TNF) agents have ...

  2. Mayo Clinic Researchers: TNF Inhibitors May Increase Cancer Risk in the Eye

    They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the balancing acts of medicine, the anti-inflammatory action of ...

  3. Transcriptomic Changes Before And After Anti-tnf Therapy Utilizing Optimum Therapeutic Drug Levels - Mayo Clinic

    About this study. The purpose of this study is to evaluate infliximab drug levels and anti-infliximab antibody levels in HiSCR50/IHS4 responders versus ...

  4. Rheumatoid arthritis finding may lead to new inflammation blockers - Mayo Clinic News Network

    Rheumatoid arthritis is an autoimmune disorder characterized by chronic inflammation, including high levels of a cytokine called tumor necrosis factor, or TNF.

  5. Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy - Mayo Clinic

    Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy · Overview · Participation eligibility.

  6. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Mayo Clinic

    ... Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy ... TNF Therapy. Amended Protocol to Include a Lutikizumab Open-Label Sub-study ...

  7. A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors - Mayo Clinic

    A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) ...

  8. Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease - Mayo Clinic

    ... Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ultimately require surgery despite ...

  9. Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease - Mayo Clinic

    ... Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ultimately require surgery despite ...

  10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy - Mayo Clinic

    ... Tumor Necrosis Factor (TNF) therapy. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...